William Blair Analysts Lower Earnings Estimates for VRTX

Key Points

• William Blair has revised its earnings per share estimate for Vertex Pharmaceuticals for Q3 2025 to $4.13, slightly down from the previous forecast of $4.16, while maintaining an "Outperform" rating on the stock.
• The consensus estimate for Vertex's full-year earnings stands at $15.63 per share, with other analysts providing target prices that have mostly been adjusted downward.
• Vertex Pharmaceuticals' stock recently fell by 2.6% and has a current market cap of $96.46 billion, with a 12-month price range between $372.35 and $519.88.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Equities research analysts at William Blair lowered their Q3 2025 earnings estimates for shares of Vertex Pharmaceuticals in a report issued on Tuesday, August 5th. William Blair analyst M. Minter now anticipates that the pharmaceutical company will post earnings per share of $4.13 for the quarter, down from their prior estimate of $4.16. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals' Q4 2025 earnings at $4.37 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. The firm had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm's quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the company posted ($12.83) EPS.

A number of other equities research analysts have also issued reports on the stock. Leerink Partners reiterated a "market perform" rating and set a $503.00 target price (down from $550.00) on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Wells Fargo & Company upgraded shares of Vertex Pharmaceuticals from an "equal weight" rating to an "overweight" rating and set a $460.00 target price on the stock in a report on Wednesday. UBS Group set a $553.00 target price on shares of Vertex Pharmaceuticals and gave the stock a "buy" rating in a report on Tuesday, August 5th. Wolfe Research lowered shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a report on Wednesday, May 7th. Finally, Guggenheim reduced their target price on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating on the stock in a report on Wednesday. Thirteen investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $497.10.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX traded down $9.09 during mid-day trading on Friday, reaching $366.54. 3,679,339 shares of the company were exchanged, compared to its average volume of 1,989,627. The firm has a market cap of $93.98 billion, a price-to-earnings ratio of 26.20 and a beta of 0.44. The firm's 50-day simple moving average is $450.77 and its 200 day simple moving average is $465.77. Vertex Pharmaceuticals has a 1 year low of $364.66 and a 1 year high of $519.88.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of VRTX. Activest Wealth Management purchased a new position in Vertex Pharmaceuticals during the 1st quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd grew its position in Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 45 shares during the last quarter. Access Investment Management LLC purchased a new position in Vertex Pharmaceuticals during the 2nd quarter worth $27,000. Legacy Investment Solutions LLC purchased a new position in Vertex Pharmaceuticals during the 2nd quarter worth $29,000. Finally, Mascagni Wealth Management Inc. purchased a new position in Vertex Pharmaceuticals during the 4th quarter worth $31,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Bruce I. Sachs purchased 5,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The shares were purchased at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the purchase, the director directly owned 45,000 shares of the company's stock, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.